Core Viewpoint - The Hong Kong biotech sector is experiencing a valuation recovery, with Baojie Pharmaceutical-B (02659) recently listed and announcing a plan for H-share full circulation, converting approximately 63.12 million unlisted shares into tradable H-shares, representing 19.36% of the total share capital [1][2]. Group 1: H-share Full Circulation - The H-share full circulation plan addresses the trading qualification of shares rather than the timing of their trading, enhancing the financial attributes and pricing efficiency of previously static domestic shares [2]. - This move allows Baojie Pharmaceutical to improve liquidity and valuation, enabling major shareholders to engage in financing, equity swaps, or mergers and acquisitions [2]. - The existence of a lock-up period acts as a buffer against immediate stock price impacts, ensuring a stable market environment for the increased liquidity [2]. Group 2: Commercialization Considerations - The implementation of full circulation aims to align shareholder interests with the company's long-term performance, supporting its unique "scenario-driven" strategy [3]. - Baojie Pharmaceutical has developed a "pyramid" pipeline, and the full circulation is expected to attract long-term institutional investors who understand the underlying logic of biopharmaceuticals [3]. - The core product KJ017, a hyaluronidase, is the first of its kind in China to enter the NDA stage, representing a strategic platform that can enable significant advancements in drug delivery [4]. Group 3: Strategic Implications - The full circulation plan links the wealth incentives of the domestic entrepreneurial team to the market performance of rare assets, enhancing their strategic focus on overcoming challenges in the industrialization of protein drugs [5]. - This initiative positions Baojie Pharmaceutical to evolve from a technology-focused biotech company to a biopharma with mature operational capabilities, supported by liquidity premiums that stabilize stock performance [5]. - The company aims to demonstrate that true value creation stems from optimizing capital structure and enhancing the efficiency of medical resource allocation, rather than short-term profit-taking [5].

Core Viewpoint - The Hong Kong biotech sector is experiencing a valuation recovery, with Baoyi Pharmaceutical-B (02659) recently listed and announcing a plan for H-share full circulation, converting approximately 63.12 million unlisted shares into tradable H-shares, representing 19.36% of the total share capital [1][2] Group 1: H-share Full Circulation - The H-share full circulation plan addresses the trading qualification of shares rather than the timing of their trading, enhancing the financial attributes and pricing efficiency of previously static domestic shares [2] - This move allows Baoyi Pharmaceutical to improve liquidity, enabling major shareholders to engage in financing, equity swaps, or mergers and acquisitions, while the existing lock-up period mitigates immediate stock price impacts [2][3] Group 2: Commercialization Considerations - The implementation of full circulation aims to align shareholder interests with the company's long-term performance, supporting its unique "scenario-driven" strategy [3] - Baoyi Pharmaceutical's pipeline, including products like SJ02, KJ017, and KJ103, benefits from increased shareholder structure optimization and the introduction of international capital that understands the underlying logic of biopharmaceuticals [3][4] Group 3: Operational Impact - The full circulation plan provides institutional backing for the commercialization of Baoyi Pharmaceutical's core pipeline, particularly KJ017, which is the first and only product in China to enter the NDA stage, breaking global technical monopolies [4][5] - The plan links the wealth incentives of the domestic entrepreneurial team to the market performance of these scarce assets, enhancing their strategic focus in overcoming challenges in the industrialization of protein drugs [5] - Overall, the full circulation enables Baoyi Pharmaceutical to transition from a technology-focused biotech to a mature biopharma, providing flexibility for future mergers or technology licensing through optimized capital structure [5]

Core Insights - Baoyi Pharmaceutical successfully completed a new share issuance of approximately HKD 1 billion, attracting significant attention in the capital market with an oversubscription of 6.59 times for international placements and 3526.34 times for public offerings in Hong Kong [1] - The company is expected to officially list on the Hong Kong Stock Exchange on December 10, 2025, with strong initial trading performance reflected in a closing price of HKD 56, representing a 112.28% increase from the offering price of HKD 26.38 [1] - Notable cornerstone investors include Anke Biotechnology, DC Alpha SPC, and Guotai Junan Securities, collectively subscribing for HKD 200.6 million, which accounts for 20.06% of the total fundraising [1] Business Model and Product Pipeline - Baoyi Pharmaceutical operates in the clinical and commercialization stages of biotechnology, focusing on developing and providing recombinant biopharmaceuticals using synthetic biology technology in China [2] - The company targets four independent and high-value therapeutic markets, including large-volume subcutaneous delivery, antibody-mediated autoimmune diseases, assisted reproductive drugs, and transformative products replacing traditional biochemical products [2] - Key products include KJ017, the first recombinant hyaluronidase in China for large-volume subcutaneous delivery; KJ103, a global first with "best-in-class" potential for low pre-stored antibodies; and SJ02, a long-acting follicle-stimulating hormone drug for assisted reproduction [2] Financial Performance - Baoyi Pharmaceutical's financial performance shows promising growth, with revenues of RMB 6.93 million, RMB 6.16 million, and RMB 41.99 million for the six months ending June 30 in 2023, 2024, and 2025, respectively [2] - The corresponding gross profits for the same periods were RMB 6.78 million, RMB 5.02 million, and RMB 41.73 million, indicating strong profitability potential [2] - As of June 30, 2025, the company reported cash and cash equivalents of RMB 453 million, reflecting a solid cash reserve [2] Use of Proceeds - The funds raised from the IPO will be allocated to the research and commercialization of core products (KJ017, KJ103, and SJ02), advancing existing pipeline products, optimizing proprietary synthetic biology technology, enhancing production capacity, and general corporate purposes [3] - The company aims to leverage its steady revenue growth, reasonable valuation, and expanding market space to translate into tangible performance returns over time [3]

Core Viewpoint - Shanghai Baoji Pharmaceutical Co., Ltd. is preparing for an IPO on the Hong Kong Stock Exchange, with funds primarily allocated for the development and commercialization of core products and expansion of production capacity [1][2]. Group 1: IPO Details - The company has submitted its hearing materials and is expected to list soon, with CITIC Securities and Cathay Securities acting as joint sponsors [1]. - The funds raised will support clinical trials and regulatory filings for core products KJ017, KJ103, and SJ02 in various regions [1]. Group 2: Product Development - The company focuses on four strategic areas: large-volume subcutaneous delivery, antibody-mediated autoimmune diseases, assisted reproduction, and recombinant biopharmaceuticals [2]. - It has developed 12 research products, including three core products, with SJ02 already approved by the National Medical Products Administration (NMPA) [2]. - KJ017 is in the NDA stage, while KJ103 is in Phase III clinical trials [2]. Group 3: Technology and Production - The company aims to optimize its proprietary synthetic biology technology platform to develop new drug candidates [1]. - Plans include enhancing and expanding production capacity, including the construction of a new production base in Shanghai and upgrading existing facilities [1].